Palo Alto, California, and Needham, Massachusetts – Nov 3, 2025 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present data from its anti-CD47 research at the American Heart Association (AHA) Annual Scientific Session 2025, taking place in New Orleans, Louisiana, November 7 – […]

-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- Palo Alto, California, and Needham, Massachusetts – June 2, 2025 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced the dosing of the first patient in its proof-of-concept MATADOR Phase 2a study in Australia,

Palo Alto, California, and Needham, Massachusetts – March 17, 2025 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present results from the Phase 1 study of BRB-002 in healthy volunteers at the American College of Cardiology (ACC) Annual Scientific Session 2025, taking place

Palo Alto, California, Needham, Massachusetts and Melbourne, Australia – January 8, 2025 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced positive results from a recently completed Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a first-in-class, immune modulating protein therapy that targets CD47 for treatment

Palo Alto, California, Needham, Massachusetts and Melbourne, Australia – October 29, 2024 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced the completion of enrollment in its Phase 1 study evaluating BRB-002 in healthy volunteers. This randomized, placebo-controlled, double-blinded, single ascending dose study is evaluating the safety, tolerability

Palo Alto, California, and Needham, Massachusetts – June 4, 2024 – Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of cardio-immunology, today announced the appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary. “I am thrilled to welcome Georgette and

Palo Alto, California and Melbourne, Australia – April 29, 2024 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the first human participants have been dosed in a Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a novel protein therapy targeting CD47 that is being

Collaboration aims to discover novel bispecific proteins targeting immune modulators and inflammatory pathways implicated in cardiovascular disease Palo Alto, California, and Zhuhai, China – February 26, 2024 – Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, today announced a multi-year research collaboration agreement.

PALO ALTO, Calif. – Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present research at the upcoming American Heart Association Scientific Sessions conference, which will take place from November 11-13, 2023 at the Pennsylvania Convention Center in Philadelphia, PA. The abstract, titled “Blockade of CD47 Using

Founders, Executive Team, and Advisors are recognized scientific and clinical pioneers in the fields of immunology and cardiology Series A financing co-led by ARCH Venture Partners and Deerfield Management with participation from GV, Koch Disruptive Technologies, Alexandria Venture Investments, and others PALO ALTO, Calif. – Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies